AIM (AIM ImmunoTech) Inventory Turnover: 0.00 (As of Mar. 2026)

What is AIM ImmunoTech Inventory Turnover?

AIM ImmunoTech AIM +4.23% 33 Inventory Turnover is 0.00 as of Mar. 2026. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.64 (Possible Value Trap). The stock has 6 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. AIM ImmunoTech's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil. AIM ImmunoTech's Average Total Inventories for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. AIM ImmunoTech's Days Inventory for the three months ended in Mar. 2026 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AIM ImmunoTech's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.00.

AIM ImmunoTech (AMEX:AIM) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AIM ImmunoTech's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	0	/	0.004	*	365 / 4
	=	0.00

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AIM ImmunoTech's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	0	/	0.022
	=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

AIM ImmunoTech Inventory Turnover Related Terms

AIM ImmunoTech Inventory Turnover Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's Inventory Turnover can be seen below:

AIM ImmunoTech Inventory Turnover Chart

AIM ImmunoTech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventory Turnover

Get a 7-Day Free Trial

0.00

AIM ImmunoTech Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

33GF Score

AIM ImmunoTech Inc AIM

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

AIM ImmunoTech Inventory Turnover Calculation

AIM ImmunoTech's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Inventory Turnover (A: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2025 )	/ (	(Total Inventories (A: Dec. 2024 )	+	Total Inventories (A: Dec. 2025 ))	/	count )
=	0.128	/ (	(0	+	0)	/	1 )
=	0.128	/	0
=	N/A

AIM ImmunoTech's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	0.004	/ (	(0	+	0)	/	1 )
=	0.004	/	0
=	N/A

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.00 mean?

AIM ImmunoTech (AIM) has a Inventory Turnover of 0.00 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on AIM ImmunoTech and its competitors.

Is AIM ImmunoTech's Inventory Turnover too high?

AIM ImmunoTech's current Inventory Turnover is 0.00. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does AIM ImmunoTech's Inventory Turnover compare to RVPH and BOLT?

AIM ImmunoTech's Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Biotechnology company?

A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is AIM ImmunoTech stock overvalued right now?

Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.64, compared to a current price of $0.30 — trading 88.8% below its estimated fair value. The current Inventory Turnover is 0.00. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Inventory Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (AIM) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of $0.30 is trading 88.8% below its estimated GF Value™ of $2.64. GuruFocus considers AIM ImmunoTech to be Possible Value Trap.

Key valuation signals for AIM:

Inventory Turnover: 0.00
GF Value™: $2.64 vs. price of $0.30 (88.8% below fair value)
GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM ImmunoTech Business Description

Industry Healthcare Biotechnology

Comparable Companies RVPH BOLT ERNA PMCB SYBX BRTX ASBP CVKD JSPR CURX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 0A4Y:UK

Address 2117 SW Highway 484, Ocala, FL, USA, 34473

Website https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

33GF Score

Get the complete analysis for AIM

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30

Price

$2.64

GF Value

View AIM Analysis

See Inventory Turnover data for all stocks →